Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Reddy's Laboratories gains for sixth straight session
Dr Reddy's Laboratories rose 2.34% to Rs 1,382.20 on Monday, extending gains for the sixth consecutive session.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories achieves 6.16% return in one week
Stocks to Watch today: HCL Tech, HDFC Bank, Turtlemint, Hexaware Tech, IRFC
Stocks to Watch today, June 29: Tata Motors PV, Torrent Power, Dr Reddy's Laboratories, Aurobindo Pharma, KEC International, and Adani Ports are among the top stocks to watch during today's trade
Dr Reddy's Labs receives seven USFDA observations for Hyderabad facility
Dr Reddy's Laboratories announced that US Food and Drug Administration (USFDA) completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad, conducted between 16th June to 25th June 2026.
Dr Reddy’s receives Form 483 with 7 observations after USFDA inspection at Hyderabad facility
Shares of Dr Reddy's Laboratories Ltd ended at ₹1,351.00, up by ₹22.65, or 1.71%, on the BSE.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories sees modest gains
India needs innovation at scale to fulfill ambition of becoming global discovery hub: Dr Reddy's
India must shift from minor advancements to large-scale innovation to become a global discovery hub, according to Dr. Reddy's Laboratories Chairman Satish Reddy. He emphasized the need for robust translational research pathways to ensure scientific breakthroughs benefit patients. The company's white paper highlights that stronger collaboration between academia, industry, and government is crucial for translating research into accessible healthcare solutions and overcoming existing challenges.
Dr Reddy's Labs Q1 Results: Date, Dividend, Share Price History, And More
Dr Reddy's Laboratories Ltd. saw an 86% YoY (year-on-year) plunge in Q4 net profit.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories achieves notable returns
Nomura expects shares of this drugmaker to rise 37% on renewed branded generics, consumer biz focus
Nomura, in its note, said that Dr. Reddy's Laboratories has sharpened its focus on branded generics and consumer business, a shift reflected in acquisitions, organic investments and recent changes to the management council.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories experiences slight decline in weekly returns
